Background: TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients. Methods: We measured mRNA transcripts of fulllength TIMP1 (TIMP1-v1) and the novel splice variant lacking exon 2 (TIMP1-v2) by use of real-time RT-PCR in frozen primary tumor samples. Transcript concentrations are correlated with histomorphological and biological factors, TIMP-1 protein, and distant metastasisfree survival (MFS) and OS time. Results: TIMP1-v1 and TIMP1-v2 alone were not informative with respect to predicting prognosis. However, the PCR assay designed to measure the combination of v1 ؉ v2 showed that high concentrations of this combination were associated with good prognosis. In Cox multivariate regression analysis, which also included the traditional prognostic factors, increasing concentrations were independently associated with prolonged MFS (P ‫؍‬ 0.004) and OS (P ‫؍‬ 0.048). Including TIMP-1 protein and TIMP1-v1؉v2 mRNA together in the multivariate model revealed that protein and mRNA were both independently associated with prognosis, with hazard ratios pointing in opposite directions. Conclusion: High concentrations of TIMP1-v1؉2 mRNA are associated with good prognosis in patients with primary breast cancer. Since high concentrations of
Tissue inhibitor of metalloproteinases-1 (TIMP-1) 3 
is one of the naturally occurring inhibitors of matrix metalloproteinases (MMPs). A number of studies have demonstrated an association between high tumor-tissue concentrations of TIMP1
4 mRNA and TIMP-1 protein and a poor prognosis for breast cancer patients (1) (2) (3) (4) (5) (6) (7) . However, TIMP-1 overexpression in malignant cells has also been associated with decreased proliferation (8 ) and with favorable clinical outcome, particularly in lymph node-negative (LNN) patients (8, 9 ) , or has not been associated with breast cancer prognosis at all (10 ) . One of the reasons for these contradictory reports might be the multifunctional roles ascribed to this protein. TIMP-1 not only inhibits MMPs (11, 12 ) but also affects cellular proliferation (13, 14 ) , apoptosis (15) (16) (17) , and angiogenesis (18 ) , both dependent on and independent of its MMP-inhibiting function. Furthermore, TIMP-1 may exist in multiple molecular forms in the cancer environment and in circulation, e.g., in complex with other proteins or as differentially glycosylated variants. Cox regression analysis of recurrence-free survival in breast cancer patients suggested that a score based on both uncomplexed and total TIMP-1, reflecting the tumor level of TIMP-1/MMP complexes, would be a more precise estimate of prognosis than total TIMP-1 alone (19 ) .
In analogy with free and complexed TIMP-1 protein, the prognostic value of TIMP-1 may be improved by detection of specific splice variants of TIMP1 mRNA. Furthermore, biological understanding of TIMP-1 protein and its gene might help in understanding the controversial findings about TIMP-1 with respect to tumor development and prognosis. To address this, we analyzed mRNA concentrations of the common full-length variant of TIMP1 (v1) and a newly discovered splice variant (v2) lacking exon 2 in a large cohort of 1301 primary breast tumors. We related TIMP1-v1 and v2 expression with histomorphological and clinical factors, mRNA expression of the proliferation marker Ki-67, and total TIMP-1 protein concentrations. Finally, we investigated whether mRNA expression of the TIMP1 splice variants adds to the prognostic value of total TIMP-1 protein.
Patients and Methods patients
A protocol for studying biological markers associated with disease outcome was approved by the medical ethics committee of the Erasmus Medical Center Rotterdam, The Netherlands (MEC 02.953). The present study, in which coded tumor tissues were used, was performed in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http:// www.fmwv.nl/). Tumor samples were originally submitted to our reference laboratory from 25 regional hospitals for measurements of steroid hormone receptors. Guidelines for primary treatment were similar for all hospitals. To avoid bias, tumors were selected from our tumor bank at the Erasmus Medical Center (Rotterdam, The Netherlands) by processing all available frozen tumor samples from female patients with breast cancer who entered the clinic during 1979 -2001 from whom detailed clinical follow-up was available. Further inclusion criteria were as follows: Ͼ100 mg frozen tissue available, invasive breast cancer, no previous other cancer (except basal cell skin cancer or early-stage cervical cancer stage Ia/Ib), no 2nd primary breast tumor at first relapse, no adjuvant systemic treatment for the LNN patients, and Ͼ30% invasive tumor cell nuclei. Of the remaining samples, 8% were excluded because of poor RNA quality.
The remaining 1301 patients were treated either with breast-conserving surgery (44%) or with modified mastectomy (56%); 931 patients (72%) received adjuvant radiotherapy. During this period, 195 of the 620 lymph nodepositive (LNP) patients did not receive adjuvant systemic therapy; 425 of the LNP patients were treated with adjuvant systemic therapy, of these patients 197 received hormonal therapy, 210 chemotherapy, and 18 received combination therapy. Routine postsurgical follow-up and definition of time to metastasis were as described (20 ) . Median follow-up was 92 months (range 3 to 248 months).
Six hundred sixty-nine (51%) patients developed a distant metastasis and count as events in the analysis for metastasis-free survival (MFS). Seventy-two patients (6%) died without evidence of disease and were censored at last follow-up in the analysis of MFS. Five hundred twenty-six patients (40%) died after a previous relapse. Thus, 598 patients (46%) were counted as events in the analysis of overall survival (OS). Tumor staging was according to the Union Internationale Contre le Cancer tumor node metastasis classification. Other relevant patient and tumor characteristics are listed in Table 1 (see also Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/ issue7).
tissue processing and estimation of the amount of invasive tumor cells
We processed tissue and estimated amount of invasive tumor cells as described (21, 22 ) . Only specimens with at least 30% of the nuclei of epithelial tumor cell origin and distributed uniformly over at least 70% of the hematoxylin-eosin-stained tissue section area were included. Furthermore, we dichotomized our tumor cohort at the median of 70% tumor cell nuclei in stroma-rich tumors (primary tumors containing Ն30% stromal components) and stroma-poor tumors (primary tumors containing at least 70% tumor cells).
rna isolation, cdna synthesis, and quantification of specific mrna species RNA isolation, cDNA synthesis, quantification of specific mRNA species, and quality control checks were done as described in detail (21 ) . We performed real-time RT-PCR in an ABI Prism 7700 Sequence Detection System (Applied Biosystems) and a Mx3000P Real-Time PCR System (Stratagene) using both Assay-on-Demand from Applied Biosystems and the intron-spanning forward and reverse primer combinations at the conditions shown in Supplemental Data Table 2 . RT-PCR products generated with these primers by cell lines and cancer tissue samples were gel-purified and sequenced (AGOWA, Berlin, Germany), and sequences were confirmed by BLAST search as described (23 ) . Primer sequences for ESR1, PGR, and the housekeeping genes have all been described, as have the PCR reactions and validations performed to ensure PCR specificity (21 ) . To measure concentrations of the proliferation marker Ki-67, we used the Hs00606991 m1 Assay-on-Demand from Applied Biosystems. Concentrations of the target genes, expressed relative to our housekeeping set [low-abundance housekeeping gene hydroxymethylbilane synthase (HMBS, formerly porphobilinogen deaminase, PBGD), medium-abundance hypoxanthine phosphoribosyltransferase (HPRT), and highabundance ␤ 2 -microglobulin (B2M)], were quantified as follows: mRNA target ϭ 2 (mean Ct housekeeping Ϫ mean Ct target) , as described (21 ) .
esr1 and pgr mrna receptor status
We established mRNA cutpoints to define tumors as steroid hormone positive at 0.2 for estrogen receptor (ER) and 0.1 for progesterone receptor (PGR). We compared these mRNA cutoffs with the established protein cutpoints of 10 fmol/mg protein in the 1203 samples with known protein concentrations as established by ELISA. For ER, sensitivity and specificity were 93% and 72%, respectively, and positive and negative predictive accuracy were 90% and 81%. For PGR, sensitivity and speci- and its 95% CI were derived from these results. The proportionality assumption was investigated with a test based on the Schoenfeld residuals. We used Kaplan-Meier survival plots and log-rank tests for trend to assess the differences in time of the predicted high-risk, intermediate-risk, and low-risk groups of patients. All tests were 2-sided, and P Ͻ0.05 was considered statistically significant.
Results

correlations between real-time timp1 pcr assays
In our initial screening using combinations of primers located 2 exons apart to cover the 6 exons of TIMP1, we measured mRNA transcripts of two variants of TIMP1 in a set of cultured cell lines and primary breast tumors: full-length TIMP1 (v1) and a novel variant lacking exon 2 (v2). The identification of these mRNA variants was confirmed by gel electrophoresis and sequence analysis and was further evaluated by real-time RT-PCR with the assays shown in Supplemental Data Table 2 in a representative selection of 180 primary breast tumors and various cell lines (Table 2) . In these analyses, only EVSA-T and CAMA-1 cells lacked expression of TIMP1-v2 (Table  2) . Although with our Taqman probe-based TIMP1-v2 assay we were unable to detect v2 transcripts above baseline in ZR75.1 and T47-D cells within 45 amplification rounds, gel analysis showed that a faint 134-bp product representative for TIMP1-v2 was produced by these cells when amplified in 45 cycles with our SYBR-based TIMP1-v1ϩ2 assay. The highest expression of TIMP1 mRNA was measured in a primary breast tumor-derived fibroblast strain (24 ) (Table 2, 19T).
All tumors readily expressed TIMP1-v1 mRNA; for only 16 of 1301 tumors were we unable to detect v2 transcripts within 45 amplification rounds. Because TIMP-1 protein overexpression has been inversely associated with cell proliferation (8 ), we matched our TIMP1 PCR data with those of the proliferation marker Ki-67 measured in the same preparations. The strength of the associations between TIMP1-v1, TIMP1-v2, TIMP1-v1ϩ2, and Ki-67 mRNA are summarized in Table 3 . Whereas TIMP1-v1ϩ2 showed a statistically significant association with TIMP1-v1, no correlation was observed with TIMP1-v2 (Spearman r s ϭ 0.51 and 0.04, respectively). TIMP1-v1ϩ2, compared with TIMP1-v1 and TIMP1-v2 separately, showed the strongest (inverse) correlation with Ki-67 (r s ϭ Ϫ0.31, Ϫ0.09, and 0.01, respectively).
associations with histomorphological and clinical factors
Associations of mRNA expression of TIMP1-v1, TIMP1-v2, and TIMP1-v1ϩ2 with patient and tumor characteris- Table 5 . TIMP1-v1 mRNA concentrations alone were not significantly associated with nodal status and steroid hormone receptor status. But the following 2 divergent observations between the various assays are notable. First, whereas concentrations measured with the TIMP1-v2 assay were associated with good prognosis only in the subgroup of LNP patients, the association of increasing concentrations measured with the TIMP1-v1ϩ2 assay and good prognosis were independent of nodal status. Second, whereas increasing concentrations of TIMP1-v1ϩ2 were associated with good prognosis exclusively in the group of ER 
correlations between timp-1 mrna and protein
To compare TIMP1 mRNA with total TIMP-1 protein, we made use of protein concentrations that were previously measured with ELISA in cytosol preparations of the same tumors (6 ) . In the 839 tumors with both measures, the highest correlation between total protein and mRNA was observed for the real time RT-PCR assay able to measure TIMP1-v1 (r s ϭ 0.34, P Ͻ0.001). The strength of the association was lower for the PCR assay able to measure both variant 1 and 2 (TIMP1-v1ϩ2) (r s ϭ 0.28, P Ͻ0.001) and inverse for the TIMP1-v2 assay (r s ϭ Ϫ0.11, P ϭ 0.01).
To ensure that our cohort of 1301 patients did not differ from the cohort of 2984 patients with protein data, we repeated all analyses for the overlapping cohort of 839 patients. We divided the protein concentrations in 3 equal parts to classify the tumors at the protein level as high vs low 1.42, P ϭ 0.010), which is in agreement with the original study, where high tumor tissue concentrations of TIMP-1 protein were identified as an independent marker of poor prognosis in 2984 primary breast cancers (6 ) . Next, we similarly compared the prognostic value of mRNA concentrations measured with our TIMP1-v1, v1ϩ2, and v2 PCR assays in these 839 patients. Only increasing concentrations of TIMP1-v1ϩ2 mRNA were significantly associated with a prolonged MFS in univariate analysis (HR intermediate vs low 0.81, HR high vs low 0.59, P Ͻ0.001) and multivariate analysis (HR intermediate vs low 0.89, HR high vs low 0.66, P ϭ 0.020).
Finally, we explored a potential interaction between TIMP-1 protein and TIMP1 mRNA with respect to MFS. No such interaction was observed (P ϭ 0.56). Including log-transformed continuous concentrations of both TIMP-1 protein and TIMP1-v1ϩ2 mRNA to the base multivariate model for MFS revealed that TIMP-1 protein and TIMP1-v1ϩ2 mRNA were both independently associated with prognosis, with HRs pointing in opposite directions (HR 1.36, 95% CI 1.16 -1.61, P Ͻ0.001, n ϭ 839 for protein and HR 0.78, 95% CI 0.69 -0.87, P Ͻ0.001, n ϭ 839 for mRNA).
Discussion
Many research groups have investigated the link between prognosis in breast cancer and TIMP-1 protein or mRNA measured in primary tumors and TIMP-1 protein in serum/plasma, with conflicting results (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . In agreement with earlier studies on TIMP1 mRNA (9, 10 ) , but in contrast to other studies (1, 3, 4 ) , we were unable to confirm that high concentrations of TIMP1 mRNA were associated with poor prognosis similar to results for TIMP-1 protein. However, mRNA transcript concentrations cannot always be compared with protein concentrations. This was confirmed in this study, where we found a rather poor correlation between full-length TIMP-1 mRNA and TIMP-1 protein. In our view, the apparently contrasting findings between the prognostic value of TIMP1 mRNA expression and TIMP-1 protein may imply that key regulators of TIMP-1 protein involved in an adverse outcome act posttranscriptionally. Such regulatory mechanisms affecting protein concentrations, activity, and stability can act at the level of mRNA translation, protein folding, glycosylation, and (proteosomal) protein degradation. This possibility needs further investigation. Our main purpose was to investigate the potential prognostic value of TIMP1 mRNA and a newly discovered splice variant to gain more knowledge on the biology of TIMP-1 in breast cancer. To address this, our retrospective study that included RNA preparations from tumor tissue obtained from 1301 patients suffering from primary breast cancer is, to the best of our knowledge, the largest study performed on the mRNA concentrations of TIMP1 to date. Because of different assay conditions, absolute values of real-time RT-PCR assays can be compared only within an assay, and values from different assays, such as our 2 assays measuring individual transcripts of TIMP-v1 and TIMP-v2, cannot simply be added. With our multiplex TIMP1-v1ϩ2 assay that measures both transcripts in the same reaction with the same primer pairs, we corrected as much as possible for such differences in assay conditions. However, by measuring both transcripts in the same reaction, we cannot exclude that the shorter (v2) variant was favored relative to the larger (v1) variant.
All tumors expressed full-length TIMP1-v1 mRNA; we were unable to detect v2 transcripts for only 16 of 1301 tumors. Sequence analysis of TIMP1-v2 has already revealed that this variant lacking exon 2, if translated, is probably a soluble, intracellular protein lacking part of the region that directs the main inhibitory MMP activity Clinical Chemistry 53, No. 7, 2007 (unpublished data). It is therefore unlikely that a putative protein of TIMP1-v2 forms complexes with MMPs, and thus it probably exhibits a biological function different from full length TIMP-1-indeed, our data suggest that. We found that TIMP1-v1 mRNA concentrations increase with age, are higher in ER/PGR-positive tumors, and are higher in smaller-sized and moderately differentiated to well differentiated tumors. In contrast to some reports (3, 4, 9 ) , but in agreement with another report (10 ), TIMP1-v1 mRNA concentrations were not different in our cohort of 620 LNP patients compared with the group of 681 LNN patients. These discrepancies might be due to the relatively small sample sizes in the earlier studies (n ϭ 30 LNN and 24 LNP (3 ); n ϭ 49 LNN and 66 LNP (4 ). Separate evaluation of TIMP1-v2 in our patient cohort revealed a strong inverse correlation with age and no correlation with ER, PGR, grade, and tumor size. In addition, only for TIMP1-v2, concentrations were higher in stroma-rich compared with stroma-poor primary breast tumors. The lack of a correlation between ER and TIMP1-v2 concentrations suggests that TIMP1-v2, unlike TIMP1-v1, is regulated by an ER-independent mechanism. Moreover, the lower TIMP1-v2 and higher TIMP1-v1 mRNA concentrations in the older age group support our hypothesis that v2 is regulated by a different mechanism. Another observation we made is the relatively strong negative correlation between the proliferation marker Ki-67 and TIMP1-v1ϩ2. No such correlation was observed for the TIMP1 assays able to measure the variants separately. This suggests that only the combined action of full-length TIMP-1 and its del-2 variant are effectively able to downregulate proliferation or monitorreduced proliferation.
We recently raised the hypothesis that high concentrations of total TIMP-1 protein are not necessarily associated with poor prognosis but that the association depends on the ratio of uncomplexed/total TIMP-1 (19 ) . In analogy with this, our present study shows that TIMP1-v1 mRNA and TIMP1-v2 mRNA alone were not associated with prognosis. However, our real-time RT-PCR assay developed to measure both transcripts at the same time revealed that high mRNA concentrations of the combination of both variants were associated with low tumor aggressiveness. Whether changing the balance between full-length TIMP-1 and its variant lacking exon 2 has potential as a possible therapeutic approach to reduce tumor aggressiveness remains to be investigated. To establish this, and since it is only the actual protein that is biologically active, variant-specific immunohistochemistry and a quantitative assay (ELISA) able to measure the putative del-2 protein in relation to full-length TIMP-1 protein are required.
In conclusion, this retrospective study on a large cohort of primary breast cancers provides evidence that the combined expression of full-length TIMP1-v1 mRNA and its v2 variant lacking exon 2 are associated with low tumor aggressiveness. This splice variant-dependent association might help our understanding of the role of TIMP-1 with respect to breast cancer. 
